The systemic problems of the PCLO trial of PSA screening

A Letter to the Editor published in this week’s issue of the New England Journal of Medicine has, yet again, pointed out that the US-based PCLO trial was badly flawed and was never, in fact, a trial of screening against no screening. … READ MORE …

Re-analysis of data from the PCLO screening study — what is truth?

A re-analysis of data from the prostate cancer screening arm of the Prostate, Lung, Colon, and Ovarian  (PLCO) cancer screening study has now stated that, “Selective use of PSA screening for men in good health appears to reduce the risk of [prostate cancer-specific mortality] with minimal overtreatment.” … READ MORE …

An important statement from the prostate cancer advocacy community

Prostate Cancer International, the parent of The “New” Prostate Cancer InfoLink, is one of several major US prostate advocacy organizations that came together to issue a joint statement this morning. The statement is in response to the publication of two articles on screening for prostate cancer, which appeared last week in the New England Journal of Medicine. … READ MORE …

The PCLO trial: an update

The Prostate, Colorectal, Lung and Ovarian cancer screening trial (the PCLO trial) is the major US trial designed to investigate whether screening for these four cancers actually affects long-term mortality rates, and is the only truly randomized, controlled trial of screening for prostate cancer. … READ MORE …